<DOC>
	<DOCNO>NCT00380770</DOCNO>
	<brief_summary>Kaposi 's sarcoma ( KS ) common malignancy associate HIV/AIDS . Therapy cancer , cause substantial morbidity , suboptimal resource poor setting . The reason : advanced state immunosuppression patient present clinical care , concomitant opportunistic infection , non- availability antiretroviral therapy ( ART ) , non-availability toxicity chemotherapy ( CXT ) , available , patient full blown AIDS , prohibitive cost bone marrow support fiscal constraint resource poor setting . A recent Cochrane Review assess effectiveness current therapeutic regimen HIV KS , focus option available resource poor setting . The major selection criterion review randomize controlled trial HIV KS adult . The main conclusion data randomize controlled trial effective treatment HIV KS sparse , particularly among people also take highly active antiretroviral therapy ( HAART ) . Alitretinoin gel effective therapy cutaneous lesion , pegylated liposomal doxorubicin effective advanced KS radiotherapy effective treat cutaneous lesion . Apart randomize trial radiotherapy , trial applicable develop setting identify . Therapy HIV KS develop country thus remain unanswered . The author conclude therapy discuss review unlikely available affordable develop country bulk HIV infection KS occur , apart radiotherapy tertiary center . However , recent change price due global alliance access initiative mean HAART likely available accessible develop country near future . South Africa commit cabinet level task force address issue . HAART propose therapy HIV KS basis restore immune competence minimize HIV tat drive KS formation . It also improve immunologic control HHV 8 possibly interrupt HIV-1- HHV-8 interaction . There one randomise trial conduct Spain compare HAART combination HAART CXT . There date prospective , randomise control trial compare efficacy HAART standard care HIV KS Africa .</brief_summary>
	<brief_title>HIV/AIDS Kaposis Sarcoma : Comparison Response HAART v HAART Plus CXT</brief_title>
	<detailed_description>DETAILED METHODOLOGY PRIMARY OBJECTIVES : 1.To compare clinical response HIV KS month 12 patient treated HAART alone treat combination HAART chemotherapy ( CXT ) . SECONDARY OBJECTIVES 1 . To monitor safety , tolerance adverse event associate regimen . 2 . To compare impact regimen baseline month 12 : 1 . CD4 count 2 . HIV1 viral load blood 3 . HIV disease progression 3 . To compare impact regimen patient Quality life ( QOL ) . 4 . To compare impact regimen patient adherence HAART . 5 To measure compare HHV8 viral load HHV8 specific CTL response baseline month 12 regimen . ( blood tissue specimen ) DESIGN Prospective , randomize , open- label trial RANDOMISATION Patients first stag GOOD risk POOR risk group accord ACTG criterion . Thereafter 4 digit computer generate number stag assign patient HAART alone HAART plus CXT ensure equal number GOOD POOR risk patient assign group . INCLUSION CRITERIA - Signed informed consent - Adults &gt; 18 year - Documented HIV positive status ( Confirmed two ELISAs HIV-1 RNA test ) - Willingness use barrier method birth control throughout course study , potential drug interaction make oral contraceptive less effective ( woman childbearing potential ) sexually active male - Histologically proven - At least five measurable , previously unirradiated cutaneous lesion must present use indicator lesion . - ECOG performance status 0-2 EXCLUSION CRITERIA - Pregnancy breastfeed - Fungating tumor KS - Symptomatic pulmonary KS - Symptomatic GI tract KS - Clinical evidence peripheral neuropathy - Clinical evidence heart disease - Total neutrophil count &lt; 1,000u/L , Hemoglobin &lt; 9.0gm/dl platelet count &lt; 75,000u/L ; serum creatinine &gt; 1.5mgh/dl , direct serum bilirubin &gt; 85 umol/l , AST ALT &gt; 2.5 time ULN . - Prior HAART ( fairly evaluate antiretroviral response KS response HAART , patient antiretroviral naïve ) - Prior radiation therapy KS sit indicator lesion . - Prior cytotoxic chemotherapy KS . - Concurrent neoplasia require cytotoxic therapy . - Life expectancy &lt; 3 month . - Circumstances , opinion investigator make unlikely patient , comply safety monitoring require participation trial . INTERVENTION Arm 1 . HAART These patient give one tablet twice daily Triomune® ( Cipla , Mumbai ) Stavudine 40mg b.d &gt; 60 kg , 30mg bd &lt; 60kg Lamivudine 150mg b.d &gt; 50 kg 2mg/kg &lt; 50 kg Nevirapine 200mg b.d ( 200mg daily first 2 week ) Arm 2 . CTX PLUS HAART HAART give . In addition , CTX administer 2 weekly interval Oncology Dept KEH VIII Hospital consist : - Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg Intravenous Doxorubicin 20mg/m2 . This regimen give 2 weekly interval . This supplied Department Oncology , KwaZulu Natal Province . PRIMARY ENDPOINTS 1 . Clinical response KS - Clinical photograph take marker lesion ( 5 accord AMC criterion ) take baseline , month 6 12 . - Lesion measurement 5 marker lesion ( per AMC RKS 02 ) ( www.amc.uab.edu ) do baseline , month 3 , month 6 , month 9 month 12 . Responses categorize complete response ( biopsy confirmation ) , complete clinical response , partial response , stable disease disease progression accord ACTG criterion . - The patient assess specialist dermatologist , train use instrument , individual decrease bias introduce inter-observer variability . We recognize potential bias study blind dermatologist know patient assignment . For reason , use establish objective criterion evaluate response . - Biopsies perform baseline , month 6 month 12 assist confirm response evaluate HIV HHV8 tissue viral load 2 . Safety toxicity DAIDS Toxicity criteria 3 . QOL EORTC QLQ C30 4 . Adherence 7 day adherence questionnaire Adherence measure use standardize validated self administer questionnaire , enable review medication previous 7 day medication specific overall adherence score .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Signed informed consent Adults &gt; 18 year Documented HIV positive status ( Confirmed two ELISAs HIV1 RNA test ) Willingness use barrier method birth control throughout course study , potential drug interaction make oral contraceptive less effective ( woman childbearing potential ) sexually active male Histologically proven At least five measurable , previously unirradiated cutaneous lesion must present use indicator lesion . ECOG performance status 02 • Pregnancy breastfeed Fungating tumor KS Symptomatic pulmonary KS Symptomatic GI tract KS Clinical evidence peripheral neuropathy Clinical evidence heart disease Total neutrophil count &lt; 1,000u/L , Hemoglobin &lt; 9.0gm/dl platelet count &lt; 75,000u/L ; serum creatinine &gt; 1.5mgh/dl , direct serum bilirubin &gt; 85 umol/l , AST ALT &gt; 2.5 time ULN . Prior HAART ( fairly evaluate antiretroviral response KS response HAART , patient antiretroviral naïve ) Prior radiation therapy KS sit indicator lesion . Prior cytotoxic chemotherapy KS . Concurrent neoplasia require cytotoxic therapy . Life expectancy &lt; 3 month . Circumstances , opinion investigator make unlikely patient , comply safety monitoring require participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Kaposi 's sarcoma</keyword>
	<keyword>Human herpesvirus 8</keyword>
</DOC>